Potassium channels play an important role in the physiology of diverse tissues, including pancreatic beta-cells, vascular smooth muscle, and the heart. Drugs which inhibit or activate potassium egress through these channels are increasingly being applied in the treatment of common human diseases such as diabetes, hypertension, and cardiac arrhythmias. The overall goal of this Project is to determine factors which account for variability in response to potassium channel modulators in humans. In vitro data indicate that the effects of inhibitors such as quinidine or glyburide can be blunted by activators such as minoxidil or pinacidil; clinical studies will assess the consequences of such combinations in modulating these compounds' antihypertensive, hypoglycemic or electrophysiologic effects. A risk with potassium channel blocking (Class III) antiarrhythmics is unpredictable and excessive QT interval prolongation and induction of the polymorphic tachycardia, torsades de pointes. The hypothesis, derived from cellular studies, that sympathetic activation will blunt the QT interval prolonging actions of Class III agents, will be tested in normal volunteers and in patients undergoing pharmacologic conversion of atrial fibrillation. Torsades de pointes is also a well-recognized complication of treatment with a number of compounds not generally thought to have electrophysiologic activity; these include the very widely-used """"""""non-sedating"""""""" antihistamines, terfenadine and astemizole, both of which are administered as racemates. To determine if enantiomer-specific therapy is justified, the electrophysiologic effects of terfenadine's enantiomers will be assessed in models predictive of torsades de pointes, and enantiomers will be administered to humans to assess the extent of racemization in vivo. This series of studies will not only provide information to increase the safety of drugs targeting potassium channels, but also will provide insights into the basic mechanisms responsible for individual variability in their desirable and undesirable actions.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
2P01GM031304-11
Application #
3778256
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Johnson, Daniel H; Gebretsadik, Tebeb; Shintani, Ayumi et al. (2013) Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. Br J Clin Pharmacol 75:997-1006
Kohli, Utkarsh; Pandharipande, Pratik; Muszkat, Mordechai et al. (2012) CYP2A6 genetic variation and dexmedetomidine disposition. Eur J Clin Pharmacol 68:937-42
Kohli, Utkarsh; Hahn, Maureen K; English, Brett A et al. (2011) Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans. Pharmacogenet Genomics 21:171-8
Ho, Richard H; Leake, Brenda F; Kilkenny, Dawn M et al. (2010) Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics 20:45-57
Kohli, Utkarsh; Muszkat, Mordechai; Sofowora, Gbenga G et al. (2010) Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception. Eur J Pain 14:154-9
Muszkat, Mordechai; Kurnik, Daniel; Sofowora, Gbenga G et al. (2010) Desensitization of vascular response in vivo: contribution of genetic variation in the [alpha]2B-adrenergic receptor subtype. J Hypertens 28:278-84
Muszkat, Mordechai; Bialer, Omer; Blotnick, Simcha et al. (2010) Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. Clin Ther 32:347-56
Li, Chun; Schwarz, Ute I; Ritchie, Marylyn D et al. (2009) Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113:3925-30
Haas, David W; Gebretsadik, Tebeb; Mayo, Gail et al. (2009) Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis 199:872-80
Kurnik, Daniel; Li, Chun; Sofowora, Gbenga G et al. (2008) Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics 18:895-902

Showing the most recent 10 out of 351 publications